Oruka Therapeutics, Inc.
ORKA
$29.91
$2.087.47%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | |||
|---|---|---|---|---|---|
| Net Income | -5.78% | -10.48% | -196.72% | ||
| Total Depreciation and Amortization | 81.82% | -- | -- | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | -12.06% | 436.87% | 3,560.47% | ||
| Change in Net Operating Assets | 93.81% | -121.76% | -144.47% | ||
| Cash from Operations | 22.35% | -109.78% | -12,322.02% | ||
| Capital Expenditure | 42.11% | -- | -- | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -- | -- | ||
| Cash from Investing | -71,507.60% | -- | -- | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | -- | -- | -- | ||
| Issuance of Common Stock | -59.28% | -- | -- | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | -- | -- | ||
| Cash from Financing | -59.90% | 106.86% | -- | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | -93.47% | -44.00% | -20.71% | ||